Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin

Diagn Microbiol Infect Dis. 2019 Apr;93(4):372-375. doi: 10.1016/j.diagmicrobio.2018.10.020. Epub 2018 Nov 10.

Abstract

Amikacin is administered with a carbapenem to treat serious infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The varying degrees of activity of the individual agents correspond to differences in activity of the 2 in combination. Amikacin and meropenem are not bactericidal against amikacin-resistant CRE.

Keywords: Amikacin; Carbapenem-resistant Enterobacteriaceae; Meropenem; Polymyxin B; Time kill.

MeSH terms

  • Amikacin / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Drug Synergism*
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Meropenem / pharmacology*
  • Microbial Viability / drug effects*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Amikacin
  • beta-Lactamases
  • Meropenem